rs778258207
Variant summary
Our verdict is Likely benign. Variant got -6 ACMG points: 1P and 7B. PP2BP4_ModerateBP6BS2
The NM_000138.5(FBN1):āc.2547C>Gā(p.Ile849Met) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000595 in 1,613,968 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/18 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000138.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -6 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152186Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000358 AC: 9AN: 251344Hom.: 0 AF XY: 0.0000368 AC XY: 5AN XY: 135900
GnomAD4 exome AF: 0.0000629 AC: 92AN: 1461782Hom.: 0 Cov.: 32 AF XY: 0.0000578 AC XY: 42AN XY: 727202
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152186Hom.: 0 Cov.: 33 AF XY: 0.0000269 AC XY: 2AN XY: 74342
ClinVar
Submissions by phenotype
Familial thoracic aortic aneurysm and aortic dissection Uncertain:3
The p.I849M variant (also known as c.2547C>G), located in coding exon 21 of the FBN1 gene, results from a C to G substitution at nucleotide position 2547. The isoleucine at codon 849 is replaced by methionine, an amino acid with highly similar properties. This variant was reported in one individual from a Marfan syndrome cohort; however, an additional FBN1 variant was also detected, and clinical information was not provided (Proost D et al. Hum. Mutat., 2015 Aug;36:808-14). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. -
This missense variant replaces isoleucine with methionine at codon 849 of the FBN1 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with Marfan syndrome; this individual also carried a different likely pathogenic missense variant in the same gene (PMID: 25907466). This variant has been identified in 9/251344 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
- -
Marfan syndrome Uncertain:2Benign:1
PP4 -
- -
This missense variant replaces isoleucine with methionine at codon 849 of the FBN1 protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with Marfan syndrome; this individual also carried a different likely pathogenic missense variant in the same gene (PMID: 25907466). This variant has been identified in 9/251344 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
not provided Uncertain:1
Identified in a patient with bicuspid aortic valve and TAAD phenotype in published literature (Proost et al., 2015); this patient also harbored a second variant in the FBN1 gene; Does not affect a cysteine residue within a calcium-binding EGF-like domain or a TGF-binding protein domain of the FBN1 gene; cysteine substitutions in the calcium-binding EGF-like domains represent the majority of pathogenic missense changes associated with FBN1-related disorders (Collod-Beroud et al., 2003); In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 27906200, 12938084, 25907466) -
FBN1-related disorder Uncertain:1
The FBN1 c.2547C>G variant is predicted to result in the amino acid substitution p.Ile849Met. This variant has been reported, along with another missense variant p.Gly1838Cys in FBN1, in one individual with Marfan syndrome (Table S2, Proost et al. 2015. PubMed ID: 25907466). This variant is reported in 0.012% of alleles in individuals of Latino descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -
not specified Benign:1
Variant summary: FBN1 c.2547C>G (p.Ile849Met) results in a conservative amino acid change in the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 3.6e-05 in 251344 control chromosomes, predominantly at a frequency of 0.00012 within the Latino subpopulation in the gnomAD database. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.2547C>G has been reported in the literature in an individual affected with Marfan Syndrome, however this patient also carried a likely pathogenic FBN1 variant (Proost_2015), suggesting that our variant of interest is in the benign spectrum. In addition, a co-occurrence with another likely pathogenic variant has been reported (FBN1 c.6871+1G>T; in an internal LCA sample), providing further evidence in support of a benign role. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. A recent study combining ACMG criteria with FBN1 gene-specific knowledge (i.e. considering critical FBN1 regions and appropriate minor allele frequency cutoffs), classified the variant as likely benign (Baudhuin_2019).To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 31227806, 27906200, 25907466). ClinVar contains an entry for this variant (Variation ID: 406321). Based on the evidence outlined above, the variant was classified as likely benign. -
Marfan syndrome;C4707243:Familial thoracic aortic aneurysm and aortic dissection Benign:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at